Envista Holdings Corp Stock Price, News & Analysis

Envista Holdings Corporation (NYSE: NVST) announced the sale of its KaVo Treatment Unit and Instrument business to Planmeca for up to $455 million, including a $30 million earn-out. This divested segment generated $357 million and $317 million in revenue in fiscal years 2019 and 2020, respectively. The deal is expected to close by the end of 2021 and will be reported as a discontinued operation starting Q3 2021. The transaction is not dependent on financing or a shareholder vote.

Envista Holdings Corporation (NYSE: NVST) announced its participation in the Baird Global Healthcare Virtual Conference on September 14, 2021, at 2:35 PM ET. Investors can access the presentation via Envista's Investor Relations website under the Events and Presentations section. Envista is a leading global provider of dental products, boasting over 30 trusted brands, including KaVo Kerr and Nobel Biocare. The company focuses on innovation and customer support to address dental professionals' needs.

Envista Holdings (NYSE: NVST) reported strong Q2 2021 results with sales reaching $740.1 million, a remarkable increase of 104.4% year-over-year. Core sales growth was 102.3%, outpacing pre-pandemic levels by 5.6% compared to Q2 2019. Net income stood at $90.1 million or $0.51 per diluted share, with adjusted EBITDA soaring to $140.4 million. The company’s adjusted EBITDA margin was 19%. Looking ahead, Envista projects full-year sales between $2.8 billion and $2.9 billion and maintains a high-teens adjusted EBITDA margin.

Envista Holdings Corporation (NYSE: NVST) announced the launch of the Envista Smile Project, a non-profit oral health foundation aimed at improving dental care access for disadvantaged communities. Currently applying for Section 501(c)(3) status, the foundation focuses on collaboration with dental professionals and Envista employees to provide care and education worldwide. CEO Amir Aghdaei emphasized the project's mission of enhancing quality of life through oral health support. This initiative aligns with Envista's broader commitment to dental care innovation and community service.

Envista Holdings Corporation (NYSE: NVST) will announce its second quarter 2021 financial results on August 3, 2021, with a conference call at 2:00 PM PT. The call will feature a discussion of these results and will last approximately one hour. Investors can access the call by dialing 866-342-8588 (U.S.) or +1 203-518-9865 (international), using conference ID #8094612. Webcast materials will be available on Envista's website before the call, with a replay accessible later.

Envista Holdings Corporation (NYSE: NVST) announced its participation in the William Blair 41st Annual Growth Stock Conference on June 1, 2021, at 9:20 AM CT, and the Stifel 2021 Virtual Jaws & Paws Conference on June 2, 2021, at 3:30 PM ET. Investors can access these events through the company's Investor Relations website. Envista, a leader in dental products, supports dental professionals globally with a broad range of solutions aimed to improve patient care and treatment outcomes.

Envista Holdings Corporation (NYSE: NVST) will participate in the Bank of America Healthcare Conference on May 11, 2021, at 11:45 AM ET. Investors can access the event via Envista's Investor Relations website.

As a leading dental products company, Envista offers a comprehensive portfolio that meets about 90% of dentists' clinical needs. The company, which separated from Danaher Corporation in 2019, focuses on continuous improvement and innovation in dental care solutions.

Envista Holdings Corporation (NYSE: NVST) reported a robust Q1 2021 with sales of $709.2 million, a 29.6% increase year-over-year. Core sales rose 29.7%, despite a 3.1% decline from discontinued products. Net income was $71.7 million or $0.41 per diluted share, while adjusted net income reached $95.4 million or $0.54 per diluted share. Adjusted EBITDA surged to $148.0 million compared to $19.4 million in Q1 2020. The CEO expressed optimism about continued growth in the dental market, emphasizing the company's dedication to organic growth and improving operating margins.